AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05580510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID
Description: This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Sacubitril/Valsartan as an active comparator.
Study NCT05580510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG OD
Description: This group of patients will receive the conventional treatment of heart failure according to the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and Empagliflozin as an experimental drug.
Study NCT06287125 — intervention group
Intervention type: DEVICE
Intervention: Renal multi-parametric MRI, Renal doppler ultrasound, Serum CD147
Description: Laboratory investigations:~erythrocyte sedimentation rate (ESR) Serum C-reactive protein (CRP) complete blood picture (CBC) liver function tests (LFT): aspartate transaminase (AST), alanine transaminase (ALT), serum albumin, serum bilirubin.~kidney function tests (KFT): serum creatinine and blood urea. Estimated glomerular filteration rate (eGFR) by CKD-EPI Creatinine Equation (2021).~Complete urine analysis for: proteinuria, urinary casts (hyaline, granular), hematuria (RBCs/ high power field), pyuria (WBCs/ high power field).~24 hour protein in urine and Creatinine clearance. Complement 3and 4(C3,C4). Immunological investigations : Antinuclear antibody (ANA) and Anti-double stranded DNA (ds-DNA).~Serum CD147~Radiological investigations:~* Chest X-ray~* Renal Doppler~* Multi-parametric MRI
Study NCT05449574 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Scale for the Assessment of Sensory Integration in Adults
Description: In people with MS and people with health of similar age, a test was performed to assess sensory integration in adults
Study NCT06174558 — intervention group
Intervention type: DEVICE
Intervention: Sleep Tracking Devices
Description: Observational Study, Smartwatches and home sleep device for sleep and respiratory monitoring
Study NCT05997030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low intensity focused ultrasound (LIFU)
Description: Subjects will undergo undergo a single LIFU of the target brain region
Study NCT04949737 — intervention group
Intervention type: BIOLOGICAL
Intervention: Helicobacter Pylori detection
Description: Biopsies will be sent to the referral anatomopathology laboratory. The search for Helicobacter pylori will be performed by immunohistochemistry. An additional blood sample for serological testing will be taken during the initial workup.~Additional data will be collected through a questionnaire.
Study NCT04696848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-516 plus Durvalumab
Description: Stage 1 : dose escalation durvalumab (1500 mg Q4W) in combination with CKD-516 at 1 of 3 planned dose levels (9, 11, or 13 mg/m2 twice a week for 3 weeks in each cycle, Q4W).~Stage 2 : durvalumab (1500 mg Q4W) in combination with CKD-516 at recommended phase 2 dose (twice a week for 3 weeks in each cycle, Q4W).
Study NCT06305507 — intervention group
Intervention type: OTHER
Intervention: Focussed laser therapy
Description: Others: Spot laser therapy~Other names:~Spot laser therapy Low Level Laser Therapy (LLLT) - Local Spot~The intervention involves the precise and focused application of low-power laser on specific areas related to plantar fasciitis. The local point technique is characterized by directing the laser directly to the painful point, seeking optimal stimulation in the affected region. This approach allows for targeted delivery of treatment to the area where pain is experienced, with the goal of maximizing the effectiveness of the therapy in reducing the symptoms associated with plantar fasciitis.
Study NCT06305507 — intervention group
Intervention type: OTHER
Intervention: Shower laser therapy
Description: Laser Therapy Sweeping~The intervention involves constantly moving the low-power laser over the areas affected by plantar fasciitis in a sweeping pattern. The sweeping technique seeks to cover a greater extent of the painful area during each treatment session. This approach differs by providing broader stimulation across the affected area, exploring the possibility of additional benefits compared to the local spot technique.
Study NCT04471103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Participation in a Delphi survey
Description: Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.
Study NCT04471103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in a Delphi survey
Description: Participants will be asked to participate in an online Delphi survey (using one of two randomly allocated methods) to rate the importance of outcomes that should be measured to determine the effect of treatment for neonatal encephalopathy. Outcomes will be prioritised on their importance in a consensus-driven manner.
Study NCT06529562 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Surgery combined with Target-reduction intensity-modulated radiotherapy
Description: in control arm
Study NCT06529562 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Surgery combined with Dose-reduction intensity-modulated radiotherapy
Description: in experimental arm
Study NCT05116982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORGONO Living Silica Acacia Gum-MMST Powder
Description: Participants will consume one capsule per day and one bottle per day. Capsule composition: Acacia Gum 336.1 mg/capsule; Monomethylsilanetriol 34.9 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
Study NCT05116982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORGONO Living Silica Malto-OSA Powder
Description: Participants will consume one capsule per day and one bottle per day. Capsule composition: Maltodextrin 311.4 mg/capsule; Silicic acid 35.6 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
Study NCT04974320 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood biomarkers
Description: All patients were obtained blood biomarkers: troponin, ST2, copeptin
Study NCT05992155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.
Study NCT05336721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: 25mg/35mg/50mg orally once daily
Study NCT05336721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000mg/m2 on Days 1-14 in a repeating 21-day cycle
Study NCT06399471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microprocessor prosthetic knee
Description: Microprocessor prosthetic knees for use in a transfemoral prosthesis
Study NCT06284798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0650-0013 A
Description: NNC0650-0013 will be administered subcutaneously or intravenously.
Study NCT06284798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration.
Study NCT05702489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZX-7101A
Description: a drug to treatment influenza in Chinese adults
Study NCT05702489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: a drug to treatment influenza in Chinese adults
Study NCT05463887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized preventive care recommendations (decision tool)
Description: Providers will receive individualized preventive care recommendations (decision tool) for eligible patients, and discuss them with patients using shared decision-making
Study NCT06224153 — intervention group
Intervention type: OTHER
Intervention: 3-day dietary record
Description: This is the conventional ingesta assessment. It will be performed twice during the study.
Study NCT06224153 — intervention group
Intervention type: OTHER
Intervention: Food Frequency Questionnaire (FFQ)
Description: This questionnaire is used to obtain information on the frequency of foods and drinks consumed over a period of time (1 week, 1 month...). It will be performed twice during the study.
Study NCT05974111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: At 5 time points (D0 (T0),morning after (T0B),D3 (T1),D5 (T2),D7(T3)) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained as well as cell free DNA methylation
Study NCT05557292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-5552
Description: Given IV
Study NCT05821088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT05821088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05821088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05821088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05821088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT05821088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT05821088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT05821088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05821088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV
Study NCT04456517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: 500 mg tablet
Study NCT04456517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ranolazine-matched placebo tablet
Study NCT06038487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading of maxillary implant overdenture
Description: The denture will be immediately connected to the implants. The abutment screw will be torqued at 15 Ncm. The Novaloc cap attachments will be picked up intra-orally using cold curing resin. To avoid contact of the resin with the surgical wound, a circular portion of a sterile rubber dam sheet will be adapted on the cap attachment once placed on the abutment during the pickup procedure. Occlusion is then checked and adjusted if necessary as well as the adaptation on the residual ridges and the patient dismissed. The patients in the test group will be instructed not to remove the prosthesis for one week.
Study NCT06038487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed loading of maxillary implant overdenture
Description: A cover screw will be seated on the implants and the flap will be sutured for a submerged healing. After 3 months of healing the implants will be exposed and connected to the prosthesis following the same prosthetic protocol as described for the test group. The abutment screw will be torqued at 35 Ncm. As post-surgical instructions, the patients will be asked not to brush the operated areas and to rinse instead with 0,12% chlorhexidine solution twice a day for 1 minute for 14 days. Pain control is provided with 400 mg ibuprofen, as needed. Soft diet is recommended for 2 weeks. The patients in the control group will be asked not to wear the denture for 7 days.
Study NCT05818943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiprodil
Description: Radiprodil is an orally active, negative allosteric modulator of the NR2B subunit of the NMDA receptor.
Study NCT06343298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MANP
Description: MANP (modified atrial natriuretic peptide) is a peptide that is being developed for treatment of difficult to control/resistant hypertension.
Study NCT06343298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matched control
Description: This is a placebo matched vehicle - Vehicle minus the active ingredient
Study NCT04463914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy app
Description: Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study NCT04463914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy app + EHR
Description: Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. The participant's primary care provider at MUSC will be provided access to a Moodivate provider portal that was developed by study team. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study NCT04463914 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
Study NCT04804007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide will be provided with prescription for etoposide 50mg orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.
Study NCT05879302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kidney Offer Shared Decision Making
Description: The intervention consists of receiving the Donor Offer Plan (DOP), reviewing a web-based educational module about donor offers including practice offer videos, followed by a discussion about the DOP with a transplant nurse coordinator.
Study NCT05116982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORGONO Living Silica Collagen Booster
Description: Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 99.9646 g/100 ml; Silicic acid 23.65 mg/100 ml; Monomethylsilanetriol 11.75 mg/100 ml. Silicon content per dose: 10.4 mg.
Study NCT05116982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 100 ml.
Study NCT05725148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART-I plus
Description: CART-I plus is a ring-type medical device that continuously monitors Atrial Fibrillation, heart rate, oxygen saturation, and blood pressure using PPG and ECG signals.
Study NCT05355363 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard Colonoscopy
Description: Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A1
Description: Usual Brand (UB) filtered, non-menthol cigarette
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: 40007388, A Non-Combusted Cigarette Variant and product use Mode A
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: 40007388, A Non-Combusted Cigarette Variant and product use Mode B
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: 40007386, A Non-Combusted Cigarette Variant and product use Mode B
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A2
Description: Usual Brand (UB) filtered, menthol cigarette
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 40007385, A Non-Combusted Cigarette Variant and product use Mode A
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product F
Description: 40007385, A Non-Combusted Cigarette Variant and product use Mode B
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product G
Description: 40007387, A Non-Combusted Cigarette Variant and product use Mode B
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product H
Description: 40007386, A Non-Combusted Cigarette Variant and product use Mode B
Study NCT05114863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product N
Description: Nicorette® White Ice Mint 4 mg nicotine gum
Study NCT05498038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
Study NCT06386224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered pain self-management (CBT Condition)
Description: Participants will login to the website for 15-20 minutes per week, and complete 5 modules focused on different skills delivered over 8 weeks (e.g., symptom identification, changing negative thoughts, activity pacing)
Study NCT06386224 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education Program
Description: Participants will login to the website for 15-20 minutes per week, and complete 5 modules focusing on pancreatitis pain topics, including: an introduction to pancreatitis, treatment options, specific therapies, surgical procedures.
Study NCT06285526 — intervention group
Intervention type: PROCEDURE
Intervention: Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy
Description: Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy
Study NCT06285526 — intervention group
Intervention type: PROCEDURE
Intervention: Cephalic DuodenoPancreatectomy
Description: Cephalic DuodenoPancreatectomy
Study NCT05144997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: ALK-positive NSCL treatment
Study NCT05287685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen media adapted School Readiness Parenting Program
Description: For the screen time adapted parenting intervention, screen time intervention components will be infused into the SRPP (described below) to address three primary areas shown in research to play an important role in healthy screen media use: (1) reducing and managing screen time use; (2) maximizing benefits of screen time content; and (3) promoting positive parent-child interactions during co-use of screen media. Psychoeducation and practice of these strategies will be incorporated into sessions of the SRPP in which relevant behavioral concepts are addressed.The screen time adapted parenting intervention will utilize the same format (large group, 8 weekly 1.5 hour sessions) as the SRPP.
Study NCT05287685 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School Readiness Parenting Program
Description: The SRPP is an 8-week parenting program for parents of preschool aged children with externalizing behavior problems. The SRPP targets child externalizing behavior problems specifically, as well as to help parents promote children's school readiness skills. The SRPP follows a group Parent-Child Interaction Therapy (PCIT) model and also uses motivational interviewing and modelling problem solving approaches. The SRPP utilizes a large group format (10-15 parents) with weekly sessions lasting 1.5 hours. The SRPP curriculum contains traditional aspects of behavioral management strategies (e.g., improving parenting skills and the parent-child relationship; discipline strategies such as time out). Specific sessions of the SRPP also directly target parental interactions during children's learning activities and setting up homework and household structure and routines. In its original form, SRPP does not address children's screen time.
Study NCT05349773 — intervention group
Intervention type: PROCEDURE
Intervention: Pneumatic tourniquet, endoscopic left radial artery harvesting
Description: Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes.
Study NCT06288217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation)
Description: Pulsed electrical stimulation of the trigeminal and vagus nerves paired with upper limb rehabilitation movements
Study NCT06288217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Limb Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke
Study NCT06288217 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Upper Limb Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke
Study NCT06288217 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Control sham stimulation of the trigeminal and vagus nerves is delivered at the start of each session. Performed alongside standard-of-care rehabilitation.